Key Clinical Message
Primary HCO is a rare, aggressive ovarian malignant tumor, morphologically resembling HCC. SALL4 can be adopted to differentiate HCO from HCC. The serum AFP, CA125 rather than HE4 can be employed as possible biomarkers to track treatment and monitor recurrence.
Keywords: hepatoid carcinoma of the ovary, HCO, SALL4, diagnosis, therapy.
(Main body of the text: 1642 words; 3 figures; 1 table; 1 supplementary table)